United Therapeutics Corporation Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
United Therapeutics Corporation (UTHR) reported Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of -$800.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-04-29.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2020-04-29
- United Therapeutics Corporation cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2020-03-31 was -$800.00K.
- United Therapeutics Corporation cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2019-12-31 was $0.00.
- United Therapeutics Corporation cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2019-09-30 was $0.00.
- United Therapeutics Corporation cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2019-06-30 was $0.00.
- United Therapeutics Corporation cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for fiscal 2019 was -$5.10M.
- United Therapeutics Corporation cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for fiscal 2017 was -$5.10M.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 3 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 6 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 9 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$800.00K 10-Q · filed 2020-04-29 | -$800.00K derived: sum of 2 quarters · filed 2020-04-29 | -$800.00K derived: sum of 3 quarters · filed 2020-04-29 | -$800.00K derived: sum of 4 quarters · filed 2020-04-29 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-26 | $0.00 derived: sum of 3 quarters · filed 2020-02-26 | -$5.10M 10-K · filed 2020-02-26 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 derived: sum of 2 quarters · filed 2019-10-30 | -$5.10M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$5.10M 10-Q · filed 2019-07-31 | ||
| 2019-03-31 | -$5.10M 10-Q · filed 2020-04-29 | |||
| 2017-12-31 | -$5.10M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |